GlassScriptPhysician profile
Arvind J Ponnambalam
NPI 1073704581
$3,081.93
in general payments reported to CMS, 2019-2025
29 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $249 · 2021: $339 · 2022: $702 · 2023: $352 · 2024: $433 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.11 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $977.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $314.94 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.72 | 2019-2023 | Stiolto Respimat |
| Genzyme Corporation | $170.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.05 | 2021-2024 | Cuvitru, Glassia |
| Grifols USA, LLC | $125.43 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $121.32 | 2019-2025 | Arikayce |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $94.87 | 2021-2024 | Dupixent |
| Pfizer INC. | $89.34 | 2019-2025 | |
| Baxter Healthcare | $75.38 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $69.33 | 2019-2022 | |
| Abbvie INC. | $66.76 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $65.74 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $60.95 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $41.29 | 2019-2024 | Fisher & Paykel Healthcare |
| Amgen INC. | $36.99 | 2024-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $35.59 | 2019 | |
| Axsome Therapeutics, INC. | $35.50 | 2023 | Sunosi |
| Genentech USA, INC. | $28.10 | 2019-2022 | |
| Shire North American Group INC | $24.38 | 2019 | |
| Advanced Respiratory, INC | $22.86 | 2020 | |
| Electromed, INC. | $19.11 | 2019 | |
| Circassia INC. | $18.38 | 2019 | |
| Gilead Sciences, INC. | $17.36 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.65 | 2021 | |
| 3b Medical, INC. | $14.99 | 2024 | Luna |
| Viatris Specialty LLC | $14.06 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Ponnambalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.